• Four genetically distinct mouse strains were bred, spanning a level of genetic diversity comparable to that seen in human populations .
• Every mouse received the same single dose of the liver carcinogen diethylnitrosamine (DEN) at the same age (15 days) under identical controlled conditions . DEN is a chemical found in tobacco smoke and some processed foods that causes DNA damage in liver cells .
• The team sequenced the genomes of almost 600 tumors and reconstructed how each tumor evolved from its original cancer-causing mutation .

Key biological finding: Across all mouse strains, tumors nearly always acquired a driver mutation activating the same MAPK signaling pathway. However, depending on the inherited genetics of the mouse, that driver mutation altered the activity of other cancer-associated signaling pathways differently and caused a striking tendency for whole-genome duplication (doubling of the entire chromosome set) in some backgrounds but not others .

Professor Odom stated: "Cancer does not arise entirely by chance. Although tumours often reach the same biological endpoint, the path to that endpoint is determined by an individual's genetic background" .

How inherited genetics influence DNA damage and cancer risk

The study builds on a well-established biological framework: cancer arises when DNA accumulates mutations that cause cells to grow uncontrollably . Environmental exposures like cigarette smoke or sunlight influence how much DNA damage occurs, but inherited genetic alterations can alter how many mutations accumulate and how cells respond .

• Inherited cancer susceptibility genes — including tumor suppressor genes, oncogenes, and genes encoding DNA repair proteins — are known to confer high risk for specific cancers when mutated .
• However, most cancer risk is not about rare high-penetrance mutations. Rather, common genetic variation across the genome creates a spectrum of susceptibility . Variation in cancer incidence among individuals exposed to the same carcinogens can be attributed to interindividual variation in genetic makeup .
• Even among individuals with inherited cancer-predisposing mutations, the actual risk of developing cancer is modified by other genetic and environmental factors .

Why most smokers never get lung cancer (and some non-smokers do)

The study directly addresses this long-standing puzzle. The researchers explicitly note: "Not everyone exposed to the same environmental risk factors will develop cancer. Most smokers do not develop lung cancer – and some non-smokers develop lung cancer. The reason why is almost certainly related to our inherited genetic makeup" .

• Previous human cohort studies have struggled to prove this causal link because individuals vary in lifestyle, environment, and exposure history, making it nearly impossible to separate genetic effects from environmental confounding .
• By controlling the environment experimentally in mice, this study provides direct causal evidence that genetic background alone — independent of exposure differences — determines tumor susceptibility, the types of mutations that arise, and the pathways by which tumors progress .

Implications for cancer screening and personalized treatment

The researchers say the findings have "implications for cancer screening and precision medicine" .

• Risk stratification and screening: Future cancer prevention and screening strategies likely need to account more carefully for inherited genetics and population diversity . Individuals with "high-susceptibility" genetic backgrounds may benefit from earlier or more frequent screening.
• Personalized treatment: The study suggests that responses to DNA-damaging cancer treatments (chemotherapy, radiation) could differ substantially depending on a patient's background genetics . If genetic background influences both the mutation processes and the signaling pathways that drive a tumor, then the same drug may work differently in patients with different inherited genomes.
• Population diversity: The finding that genetic diversity comparable to human populations produced dramatically different tumor outcomes underscores the need for cancer research and clinical trials to include diverse populations .

Dr. Sarah Aitken, first author, summarized: "If genetic background influences both cancer risk and the evolutionary path of tumors, then we need to think carefully about how we screen for cancer and how we treat it in people with different genetic backgrounds" .

• Four genetically distinct mouse strains were bred, spanning a level of genetic diversity comparable to that seen in human populations .
• Every mouse received the same single dose of the liver carcinogen diethylnitrosamine (DEN) at the same age (15 days) under identical controlled conditions . DEN is a chemical found in tobacco smoke and some processed foods that causes DNA damage in liver cells .
• The team sequenced the genomes of almost 600 tumors and reconstructed how each tumor evolved from its original cancer-causing mutation .

Key biological finding: Across all mouse strains, tumors nearly always acquired a driver mutation activating the same MAPK signaling pathway. However, depending on the inherited genetics of the mouse, that driver mutation altered the activity of other cancer-associated signaling pathways differently and caused a striking tendency for whole-genome duplication (doubling of the entire chromosome set) in some backgrounds but not others .

Professor Odom stated: "Cancer does not arise entirely by chance. Although tumours often reach the same biological endpoint, the path to that endpoint is determined by an individual's genetic background" .

How inherited genetics influence DNA damage and cancer risk

The study builds on a well-established biological framework: cancer arises when DNA accumulates mutations that cause cells to grow uncontrollably . Environmental exposures like cigarette smoke or sunlight influence how much DNA damage occurs, but inherited genetic alterations can alter how many mutations accumulate and how cells respond .

• Inherited cancer susceptibility genes — including tumor suppressor genes, oncogenes, and genes encoding DNA repair proteins — are known to confer high risk for specific cancers when mutated .
• However, most cancer risk is not about rare high-penetrance mutations. Rather, common genetic variation across the genome creates a spectrum of susceptibility . Variation in cancer incidence among individuals exposed to the same carcinogens can be attributed to interindividual variation in genetic makeup .
• Even among individuals with inherited cancer-predisposing mutations, the actual risk of developing cancer is modified by other genetic and environmental factors .

Why most smokers never get lung cancer (and some non-smokers do)

The study directly addresses this long-standing puzzle. The researchers explicitly note: "Not everyone exposed to the same environmental risk factors will develop cancer. Most smokers do not develop lung cancer – and some non-smokers develop lung cancer. The reason why is almost certainly related to our inherited genetic makeup" .

• Previous human cohort studies have struggled to prove this causal link because individuals vary in lifestyle, environment, and exposure history, making it nearly impossible to separate genetic effects from environmental confounding .
• By controlling the environment experimentally in mice, this study provides direct causal evidence that genetic background alone — independent of exposure differences — determines tumor susceptibility, the types of mutations that arise, and the pathways by which tumors progress .

Implications for cancer screening and personalized treatment

The researchers say the findings have "implications for cancer screening and precision medicine" .

• Risk stratification and screening: Future cancer prevention and screening strategies likely need to account more carefully for inherited genetics and population diversity . Individuals with "high-susceptibility" genetic backgrounds may benefit from earlier or more frequent screening.
• Personalized treatment: The study suggests that responses to DNA-damaging cancer treatments (chemotherapy, radiation) could differ substantially depending on a patient's background genetics . If genetic background influences both the mutation processes and the signaling pathways that drive a tumor, then the same drug may work differently in patients with different inherited genomes.
• Population diversity: The finding that genetic diversity comparable to human populations produced dramatically different tumor outcomes underscores the need for cancer research and clinical trials to include diverse populations .

Dr. Sarah Aitken, first author, summarized: "If genetic background influences both cancer risk and the evolutionary path of tumors, then we need to think carefully about how we screen for cancer and how we treat it in people with different genetic backgrounds" .